Kyowa Pharmaceutical, Inc Company Profile

11:47 EDT 20th March 2018 | BioPortfolio

From its foundation in 1949, Kyowa Hakko has been a global leader in the pharmaceutical industry. Today, Kyowa's expertise extends to the United States through Kyowa Pharmaceutical, Inc. headquartered in Princeton, New Jersey.


212 Carnegie CenterSuite 101
New Jersey
United States of America


Phone: 609-919-1100
Fax: 609-919-1111

News Articles [366 Associated News Articles listed on BioPortfolio]

Kyowa Kirin und Ultragenyx geben bekannt, dass Crysvita® (Burosumab) eine bedingte Zulassung ...

Kyowa Hakko Kirin Co. Ltd, (Kyowa Hakko Kirin), Kyowa Kirin International PLC (Kyowa Kirin International) und Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE: Ultragenyx) gaben Read more...

Kyowa Hakko Kirin Announces Marketing Authorisation Application for Mogamulizumab Validated by ...

Kyowa Hakko Kirin Co. Ltd.MediaHiroki Nakamura,

Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion for the Treatment of X-Linked Hypophosphatemia in Children

TOKYO, LONDON, and NOVATO, California, December 15, 2017 /PRNewswire/ -- If approved, burosumabwould be the first targeted disease-modifying treatment for XLH Kyowa Hakko Kirin Co., Ltd. (Kyowa Ha...

Ultragenyx und Kyowa Kirin geben bekannt, dass Burosumab eine positive Stellungnahme des CHMP zur Behandlung der X-chromosomalen Hypophosphatämie bei Kindern erhalten hat

Tokio, London, und Novato, Kalifornien (ots/PRNewswire) - Bei Zulassung wäre Burosumab die erste gezielte krankheitsmodifizierende Behandlung für XLH Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin)....

Kyowa Hakko Kirin gibt von der Europäischen Arzneimittelagentur verifizierten Vermarktungszulassungsantrag für Mogamulizumab bekannt

Tokio (ots/PRNewswire) - Die Kyowa Hakko Kirin Co., Ltd. (Tokio: 4151 President und CEO: Nobuo Hanai, "Kyowa Hakko Kirin" gibt heute bekannt, dass ihr Vermarktungszulassungsantrag (MAA) für Mogamul.....

Kyowa Hakko Kirin Announces FDA Acceptance for Filing and Priority Review Designation of Mogamulizumab Biologics License Application

TOKYO--(BUSINESS WIRE)-- November 28, 2017 Kyowa Hakko Kirin Co., Ltd. (TOKYO:4151) (President and CEO: Nobuo Hanai, “Kyowa Hakko Kirin”) today announces that the U.S. Food and Drug Administration...

Kyowa Hakko Kirin Announces Results of Phase 3 Clinical Study of Mogamulizumab (KW-0761) in Patients with Cutaneous T-cell Lymphoma at the American Society of Hematology 2017

TOKYO, December 11, 2017 /PRNewswire/ -- Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") announced today that the results of the Global Phase 3 study...

FDA accepts Kyowa Hakko Kirin’s BLA for lymphoma candidate

Shares of Japanese drugmaker Kyowa Hakko Kirin moved up more than 2% to 2,086 yen today, after the company…

PubMed Articles [417 Associated PubMed Articles listed on BioPortfolio]

Pharmaceutical care for patients of the third age in pharmacy organizations as a significant aspect of social gerontology.

There are questions in the article that study mutual relations of patients of elderly and senile age with pharmaceutical experts. It was revealed that pharmacy organizations are an important element i...

Pharmaceutical cocrystals as an opportunity to modify drug properties: From the idea to application. A review.

The properties of many drugs which have been available on the pharmaceutical market for a long time still need to be improved. Cocrystals are the solid state drug modification which can improve such p...

Total Health-related Costs Due to Absenteeism, Presenteeism, and Medical and Pharmaceutical Expenses in Japanese Employers.

This study aimed to examine a detailed breakdown of costs (absenteeism, presenteeism, and medical/pharmaceutical expenses), of the employees in four pharmaceutical companies in Japan.

Pharmaceutical Cocrystals: New Solid Phase Modification Approaches for the Formulation of APIs.

Cocrystals can be used as an alternative approach based on crystal engineering to enhance specific physicochemical and biopharmaceutical properties of active pharmaceutical ingredients (APIs) when the...

Editorial Special Supplement of the European Journal of Pharmaceutical Sciences on the occasion of the retirement of Professor Meindert Danhof as Professor of Pharmacology at Leiden University.

Clinical Trials [289 Associated Clinical Trials listed on BioPortfolio]

Pharmaceutical Care for Asthma Control Improvement (PHARMACI)-Study

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients.

Pharmaceutical Care for Diabetes Type 2 Patients: a Randomised Controlled Trial

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for diabetes type 2 patients. Patients will be randomly allocated to th...

Improving Compliance Among Elderly Polypharmacy Users Through Community Pharmacy Based Pharmaceutical Care Program

The aim of the project is to evaluate effectiveness of a multidimensional pharmaceutical care plan in improving compliance among elderly polypharmacy users at community pharmacy settings. ...

Impact of Collaborative Pharmaceutical Care on Hospital Admission Drug Prescriptions for Patients 65 Years of Age and Older

The primary objective of this study is to evaluate the impact of the implementation of collaborative pharmaceutical care on drug support at admission for patients 65 years of age and older...

Individualized Pharmaceutical-care in Outpatients With Cancer Pain

The purpose of the study is to investigate the impact of pharmaceutical care on cancer pain treatment for opioid-tolerant outpatients

Companies [1028 Associated Companies listed on BioPortfolio]

Kyowa Pharmaceutical, Inc

From its foundation in 1949, Kyowa Hakko has been a global leader in the pharmaceutical industry. Today, Kyowa's expertise extends to the United States through Kyowa Pharmaceutical, Inc. headquartered...

Kyowa Hakko, USA Inc.

Kyowa Hakko USA

Kyowa Hakko

Kyowa Hakko Kirin Co., Ltd.

More Information about "Kyowa Pharmaceutical, Inc" on BioPortfolio

We have published hundreds of Kyowa Pharmaceutical, Inc news stories on BioPortfolio along with dozens of Kyowa Pharmaceutical, Inc Clinical Trials and PubMed Articles about Kyowa Pharmaceutical, Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kyowa Pharmaceutical, Inc Companies in our database. You can also find out about relevant Kyowa Pharmaceutical, Inc Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record